Skip to main content
letter
. 2012 Sep 20;107(10):1761–1765. doi: 10.1038/bjc.2012.428

Table 1. Tumours included in the MED12 exon 2 mutation screening.

Tumour type N Sample type Samples from
Mesenchymal      
 Uterine leiomyosarcoma 39 FFPE PH/CFCH
  Early onset (dg⩽45 years) 27   PH
  Unselected 12   CFCH
 Sarcoma 104 Fresh frozen PH
  Soft tissue sarcoma (including two ULMS) 83    
  Bone sarcoma 21    
 Gastrointestinal stromal tumour 12 FFPE CFCH
 Extrauterine leiomyoma 42 FFPE CFCH/PH
 Endometrial polyp 54 FFPE PH
 Lipoma 35 FFPE CFCH
       
Oestrogenprogesterone dependent
 Ovarian carcinoma 122 FFPE/fresh frozen PH
  Clear cell 39    
  Serous 44    
  Mucinous 10    
  Endometrioid 10    
  NOS 19    
 Breast cancer 94 Fresh frozen OGH/PH
  Ductal 68    
  Lobular 14    
  Medullary 4    
  Other 8    
       
Haematological malignancies
 Acute myeloid leukaemia 131 Fresh/fresh frozen AAUH/MSKCC
 Acute lymphoid leukaemiaa 37 Fresh frozen AAUH
 Myeloproliferative neoplasm 96 Fresh/fresh frozen MSKCC
  Polycythemia vera 48    
  Essential thrombocytosis 48    
       
Abnormal Wnt-signalling associated
 Colorectal cancer 392 Fresh frozen FCH

Abbreviations: AAUH=Department of Hematology at Aarhus University Hospital; CFCH=Central Finland Central Hospital; FCH=Finnish Central Hospitals; FFPE=formalin-fixed paraffin-embedded; MSKCC=Memorial Sloan-Kettering Cancer Center; NOS=not otherwise specified; OGH=Department of Obstetrics and Gynecology at Helsinki University Central Hospital; PH=Department of Pathology at Helsinki University Central Hospital; ULMS=uterine leiomyosarcoma.

a

T-cell origin.